The operational multiple dosing half-life: a key to defining drug accumulation in patients and to designing extended release dosage forms.
about
Benet L Z and Galeazzi R L: noncompartmental determination of the steady-state volume of distribution, J Pharm Sci 68, 1071-1074, 1979--the backstoryProposal for defining the relevance of drug accumulation derived from single dose study data for modified release dosage formsChanges in clearance, volume and bioavailability of immunosuppressants when given with HAART in HIV-1 infected liver and kidney transplant recipients.Absorption-dependent apparent volume of distribution at steady state (V(ss)/F) in pharmacokinetic data analysis.First-dose pharmacokinetics of lithium carbonate in children and adolescents.Pharmacokinetics and drug interactions of eslicarbazepine acetate.Dedication to professor Leslie Z. Benet: 50 years of scientific excellence and still going strong!Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid Arthritis.Population modeling and simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of isoniazid in lungs.Model Linking Plasma and Intracellular Tenofovir/Emtricitabine with Deoxynucleoside Triphosphates.Measurement of betamethasone concentration in maternal serum treated for fetal lung maturity; Is it feasible?Effects of drug transporters on volume of distribution.The role of transporters in the pharmacokinetics of orally administered drugs.Real-time in vivo monitoring of magnetic nanoparticles in the bloodstream by AC biosusceptometryClearance (née Rowland) concepts: a downdate and an update.Clinical Pharmacokinetic Characteristics of Cebranopadol, a Novel First-in-Class Analgesic.Perspectives on variability in pharmacokinetics of an oral contraceptive product.Clarification of contraceptive drug pharmacokinetics in obesity.Intracellular Tenofovir and Emtricitabine Anabolites in Genital, Rectal, and Blood Compartments from First Dose to Steady State.Intermittent drug dosing intervals guided by the operational multiple dosing half lives for predictable plasma accumulation and fluctuation.Cross-species absorption, metabolism, distribution and pharmacokinetics of BI 201335, a potent HCV genotype 1 NS3/4A protease inhibitor.Comparative steady-state pharmacokinetic evaluation of immediate-release topiramate and USL255, a once-daily extended-release topiramate formulation.Pharmacokinetics and distribution of minocycline in mature horses after oral administration of multiple doses and comparison with minimum inhibitory concentrations.Nonclinical pharmacokinetics and metabolism of EPZ-5676, a novel DOT1L histone methyltransferase inhibitor.Flip-flop kinetics of ropivacaine during continuous epidural infusion influences its accumulation rate.Time of effect duration and administration interval for sitagliptin in patients with kidney failure.Safety, pharmacokinetics, and pharmacodynamics of RSLV-132, an RNase-Fc fusion protein in systemic lupus erythematosus: a randomized, double-blind, placebo-controlled study.Effects of formulation and route of administration on the systemic availability of Ex-RAD®, a new radioprotectant, in preclinical species.
P2860
Q26866089-166AB54F-204A-4CA6-9142-E90C48915D4CQ30862472-6219ED8C-3649-421C-8B9A-1EFE15A532C6Q33599107-7E699381-AB0F-4C64-AD57-6D5D286026F4Q34015139-2BCE87C2-722D-4EF9-B3F3-A8984F132639Q34257156-3F464AF7-A620-4E11-B3F1-6313E2A942FEQ34276263-D054066D-9F30-4C7B-BF28-9945CEBC96A9Q34289184-D2C4D5FA-E633-4818-A345-367167777EC0Q34529981-BB6771DF-1736-4075-BCF0-DD51C11887AFQ35960852-55FC46FF-A4D0-419E-96BD-1D2F924D9730Q36188725-15A5ADB9-9B52-457F-A71F-362E9D3408EDQ36565762-E145360F-5519-49CB-8425-58890824249DQ37214523-D84DF19B-F6C5-4D85-A750-9DECA0B72158Q37537018-F46A26E1-F6A3-4FBE-AC92-C1CFBC24CA05Q37715749-B229A9CD-407B-4BB2-AEDC-8672BC6D862CQ37813042-442902CF-1F14-4713-ABAF-0320C9DF1B77Q38721640-23899ACB-4425-4F63-8C83-9EAF8BF99C4CQ38913410-2D84736D-298F-475B-BBC5-1348077ADE0CQ38932206-E51F18DC-FF13-4DBE-97B7-AC4FD7385648Q39488594-7D1B517A-59DD-4E81-B21F-A21F9CFAF3D9Q41812987-11EF8C7A-BDF9-417C-AF18-39E650B94180Q43041164-1C2C2260-7A47-4DF4-9799-B7986B678216Q43642726-14451549-4FD5-4D62-9AAF-820DBF405132Q44672159-3D22FC36-5164-4EF3-85F9-E20F9E85600CQ46947333-429EA8F1-A79B-44D2-9D37-310EDDC6C71EQ48311857-2F10CB5F-9961-44B1-878E-F9292D288730Q51131443-9EF74821-9C5A-4DCB-A9BE-43285431F5C6Q51324016-9E70B703-7DDF-442A-B5AF-A69D4C08F3D4Q53266146-D0C3F85D-D159-4529-915B-2C22F3821F97
P2860
The operational multiple dosing half-life: a key to defining drug accumulation in patients and to designing extended release dosage forms.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
The operational multiple dosin ...... extended release dosage forms.
@en
type
label
The operational multiple dosin ...... extended release dosage forms.
@en
prefLabel
The operational multiple dosin ...... extended release dosage forms.
@en
P2860
P1476
The operational multiple dosin ...... extended release dosage forms.
@en
P2093
Leslie Z Benet
Selma Sahin
P2860
P304
P356
10.1007/S11095-008-9787-9
P577
2008-11-18T00:00:00Z